18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®)

Stroobants, Sigrid; Goeminne, Jean Charles.; Seegers, M.; Dimitrijević, Saša; Dupont, Patrick; Nuyts, Johan; Martens, Marc; Borne, Ben van den; Cole, Patricia E.; Sciot, Raf; Dumez, Herlinde; Silberman, Sandra; Mortelmans, Luc; Oosterom, Allan Van

doi:10.1016/s0959-8049(03)00073-x

Cited by 483 publications

(264 citation statements)

References 19 publications

Supporting

Mentioning

241

Contrasting

Unclassified

Order By: Relevance

“…Studies of imatinib-treated GIST patients have demonstrated that functional imaging with FDG-PET is highly predictive of subsequent anatomic response documented by CT or magnetic resonance imaging and can show treatment effects (i.e., reduction in tumor metabolic activity) as early as 24 hours after the start of therapy [20,28,29]. Combinedmodality PET/CT was demonstrated to be superior to PET and CT in detecting GIST metastases and correctly characterizing response to imatinib therapy [30].…”

Section: Case Discussionmentioning

confidence: 99%

Management of Gastrointestinal Stromal Tumors in the Imatinib Era: Selected Case Studies

et al. 2006

View full text Add to dashboard Cite

The introduction of imatinib, an orally administered inhibitor of the KIT receptor tyrosine kinase, is prompting revision of the management algorithms that have traditionally guided the treatment of gastrointestinal stromal tumor (GIST). Historically, patients with GISTs have had substantial rates of relapse as well as limited long-term survival even after complete surgical resection of a primary tumor. Imatinib has been shown to induce durable tumor responses in more than half of the patients with malignant metastatic or unresectable GISTs and to halt disease progression in an additional third. These encouraging results have led to the initiation of clinical trials of imatinib as an adjuvant or neoadjuvant therapy with surgery. Until relevant data are reported to provide definitive direction for the management of operable or potentially operable GISTs, treatment decisions must be made on the basis of the available evidence and clinical experience with imatinib. This paper presents selected case studies describing approaches to the combined use of surgery and systemic therapy that have been applied in the treatment of individual GIST patients. The management of GIST in these cases required a coordinated, multidisciplinary approach involving medical oncologists, diagnostic radiologists, gastroenterologists, surgeons, and pathologists. The Oncologist 2006;11:9-20

show abstract

Section: Case Discussionmentioning

confidence: 99%

Management of Gastrointestinal Stromal Tumors in the Imatinib Era: Selected Case Studies

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Studies of targeted therapies like imatinib, which inhibits the c-kit growth factor pathway in gastrointestinal stromal tumors, have indicated that FDG uptake is reduced within hours of starting treatment and appears to be related to a rapid decline in glucose transporter expression. [37][38][39] Similarly, it has been demonstrated that the inhibition of epidermal growth factor receptor kinase by gefitinib in lung cancer cell lines results in translocation of glucose transporters from the plasma membrane to the cytosol within 4 hours. 40 However, additional studies are needed to further elucidate the mechanisms behind the rapid decline in FDG uptake in response to these classes of drugs.…”

Section: Fdg-pet For Monitoring Tumor Responsementioning

confidence: 99%

PET/CT imaging in cancer: Current applications and future directions

Farwell

Pryma

Mankoff

2014

Cancer

196

120

View full text Add to dashboard Cite

Positron emission tomography (PET) is a radiotracer imaging method that yields quantitative images of regional in vivo biology and biochemistry. PET, now used in conjunction with computed tomography (CT) in PET/CT devices, has had its greatest impact to date on cancer and is now an important part of oncologic clinical practice and translational cancer research. In this review of current applications and future directions for PET/CT in cancer, the authors first highlight the basic principles of PET followed by a discussion of the biochemistry and current clinical applications of the most commonly used PET imaging agent, 18 F-fluorodeoxyglucose (FDG). Then, emerging methods for PET imaging of other biologic processes relevant to cancer are reviewed, including cellular proliferation, tumor hypoxia, apoptosis, amino acid and cell membrane metabolism, and imaging of tumor receptors and other tumor-specific gene products. The focus of the review is on methods in current clinical practice as well as those that have been translated to patients and are currently in clinical trials. Cancer 2014;120:3433-45.

show abstract

“…Recently, FDG-PET has been shown to be highly sensitive in detecting early responses in patients with GISTs; it has also been shown to be useful in the prediction of long-term responses to imatinib mesylate (1)(2)(3)(4)(5)(6)8). However, FDG-PET has been rarely used to report liver metastases in gastric adenocarcinoma.…”

Section: Hepatic Metastases Of Gastric Adenocarcinoma Showing Metabolmentioning

confidence: 99%

Hepatic Metastases of Gastric Adenocarcinoma Showing Metabolic Remission on FDG-PET Despite an Increase in Size on CT

et al. 2009

View full text Add to dashboard Cite

18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®)

Cited by 483 publications

References 19 publications

Management of Gastrointestinal Stromal Tumors in the Imatinib Era: Selected Case Studies

Management of Gastrointestinal Stromal Tumors in the Imatinib Era: Selected Case Studies

PET/CT imaging in cancer: Current applications and future directions

Hepatic Metastases of Gastric Adenocarcinoma Showing Metabolic Remission on FDG-PET Despite an Increase in Size on CT

Contact Info

Product

Resources

About